Cornelia M Weyand, MD
Rheumatology · Rochester
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Mayo Clinic · 4,829 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Weyand’s office at (507) 284-2511 to ask if they take your plan before you enroll.
California Medical Board record
Licence C54171 · Current
Licensed to practise in California · since 2010 · expires 2028-06-30 · Rheinisch-Westfalische Technical Academy at Aachen.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$13,593
Medicare paid this office $13,593 for 45 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 29 | $8,300 | $136 |
| New patient visit (60+ min) | 20 | $3,467 | $173 |
Who their Medicare patients are
45 Original Medicare patients in 2024. Average age 73 · Women 67% · Health risk score 1.62. Above the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Coronary heart disease 42% · Chronic kidney disease 42% · Diabetes 27% · Cancer 27%.
The office billed $46,180, Medicare allowed $17,566 and paid $13,593; for 121 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 45 | 121 | 73 | 1.62 | $46,180 | $13,593 |
| 2023 | 49 | 90 | 75 | 1.37 | $40,504 | $11,941 |
| 2022 | 46 | 105 | 73 | 1.58 | $44,903 | $13,369 |
| 2021 | 55 | 75 | 75 | 1.51 | $22,072 | $8,701 |
| 2020 | 48 | 104 | 73 | 1.56 | $27,322 | $9,154 |
| 2019 | 73 | 182 | 73 | 1.79 | $23,868 | $13,093 |
| 2018 | 74 | 215 | 72 | 1.84 | $30,218 | $16,498 |
| 2017 | 70 | 200 | 69 | 1.58 | $39,264 | $14,420 |
| 2016 | 53 | 143 | 68 | 2.33 | $33,260 | $11,183 |
| 2015 | 48 | 114 | 67 | 1.78 | $26,575 | $8,754 |
| 2014 | 56 | 157 | 68 | 2.13 | $38,407 | $12,415 |
| 2013 | 27 | 92 | 65 | 2.39 | $19,530 | $6,477 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 26 | $6,719 | $134 |
| New patient visit (60+ min) | 21 | $3,604 | $172 |
2022: 2 services
| Long return visit (40+ min) | 29 | $7,305 | $135 |
| New patient visit (60+ min) | 23 | $3,845 | $167 |
2021: 2 services
| Long return visit (40+ min) | 29 | $3,581 | $109 |
| New patient visit (60+ min) | 15 | $2,650 | $177 |
2020: 2 services
| Long return visit (40+ min) | 26 | $3,369 | $94 |
| Return visit (30+ min) | 27 | $2,974 | $69 |
2019: 2 services
| Return visit (30+ min) | 61 | $8,658 | $62 |
| Long return visit (40+ min) | 19 | $2,221 | $93 |
2018: 3 services
| Return visit (30+ min) | 57 | $9,728 | $62 |
| New patient visit (60+ min) | 20 | $3,010 | $151 |
| Long return visit (40+ min) | 15 | $1,796 | $95 |
2017: 2 services
| Return visit (30+ min) | 52 | $9,790 | $64 |
| New patient visit (60+ min) | 12 | $1,725 | $144 |
2016: 3 services
| Return visit (30+ min) | 38 | $6,654 | $66 |
| New patient visit (60+ min) | 11 | $1,647 | $150 |
| Long return visit (40+ min) | 11 | $1,167 | $97 |
2015: 1 service
| Return visit (30+ min) | 32 | $5,362 | $65 |
2014: 2 services
| Return visit (30+ min) | 32 | $5,758 | $63 |
| Long return visit (40+ min) | 22 | $2,861 | $99 |
2013: 1 service
| Return visit (30+ min) | 21 | $4,683 | $63 |
Drugs they prescribed that Part D paid
$6,787
Pharmacies billed $6,787 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 237) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
236 generic and fewer than 11 brand-name prescriptions · $6,787 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisone | 182 | $2,452 | $13 |
| Mycophenolate Mofetil | 22 | $993 | $45 |
| Alendronate | 16 | $107 | $7 |
Year by year
| 2024 | 237 | 41 | 0% (0) | None | $6,787 |
| 2023 | 209 | 34 | 0% (0) | None | $13,934 |
| 2022 | 134 | 32 | 0% (0) | None | $38,389 |
| 2021 | 123 | 27 | 0% (0) | 0% | $4,178 |
| 2020 | 249 | 39 | 0% (0) | None | $31,377 |
| 2019 | 356 | 47 | 0% (0) | 4% | $80,989 |
| 2018 | 290 | 41 | 0% (0) | None | $24,665 |
| 2017 | 230 | 32 | 0% (0) | 0% | $16,497 |
| 2016 | 198 | 24 | 0% (0) | None | $8,671 |
| 2015 | 131 | 20 | 0% (0) | None | $5,084 |
| 2014 | 144 | 18 | 0% (0) | None | $3,590 |
| 2013 | 127 | 13 | 0% (0) | None | $3,287 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Prednisone | 172 | $2,690 | $16 |
| Alendronate | 19 | $245 | $13 |
2022: 3 drugs
| Prednisone | 92 | $1,829 | $20 |
| Mycophenolate Mofetil | 12 | $1,261 | $105 |
| Alendronate | 13 | $43 | $3 |
2021: 3 drugs
| Mycophenolate Mofetil | 37 | $2,349 | $63 |
| Prednisone | 66 | $1,453 | $22 |
| Alendronate | 12 | $104 | $9 |
2020: 3 drugs
| Mycophenolate Mofetil | 70 | $3,708 | $53 |
| Prednisone | 141 | $2,836 | $20 |
| Alendronate | 22 | $184 | $8 |
2019: 4 drugs
| Humira(Cf) | 12 | $62,747 | $5,229 |
| Mycophenolate Mofetil | 100 | $8,340 | $83 |
| Prednisone | 181 | $3,909 | $22 |
| Alendronate | 17 | $156 | $9 |
2018: 2 drugs
| Mycophenolate Mofetil | 55 | $8,513 | $155 |
| Prednisone | 162 | $2,958 | $18 |
2017: 3 drugs
| Mycophenolate Mofetil | 42 | $9,760 | $232 |
| Prednisone | 133 | $2,693 | $20 |
| Alendronate | 20 | $176 | $9 |
2016: 2 drugs
| Mycophenolate Mofetil | 32 | $3,073 | $96 |
| Prednisone | 110 | $2,317 | $21 |
2015: 3 drugs
| Mycophenolate Mofetil | 15 | $1,765 | $118 |
| Prednisone | 83 | $1,341 | $16 |
| Azathioprine | 15 | $778 | $52 |
2014: 2 drugs
| Prednisone | 87 | $1,417 | $16 |
| Azathioprine | 20 | $586 | $29 |
2013: 3 drugs
| Azathioprine | 26 | $783 | $30 |
| Prednisone | 61 | $769 | $13 |
| Escitalopram | 12 | $532 | $44 |
Money from drug and device companies
$3,658 in 2024
| 2024 | 2 | 3 | $3,650 | $3,658 |
| 2023 | 4 | 10 | $14,440 | $16,580 |
| 2022 | 1 | 2 | $6,000 | $6,000 |
| 2021 | 1 | 1 | $9,500 | $9,500 |
| 2020 | 2 | 3 | $8,740 | $8,902 |
| 2019 | 1 | 18 | $13,390 | $14,239 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim International GmbH | Ofev | $3,000 | 1 payment
|
| Abbvie | Rinvoq | $658 | 2 payments
|
See all 3 published payments
| Boehringer Ingelheim International GmbH | Consulting · 2024-11-04 | Ofev | $3,000 |
| Abbvie | Consulting · 2024-08-06 | Rinvoq | $650 |
| Abbvie | Meals · 2024-06-25 | Rinvoq | $8 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $16,580
| AbbVie | None | $10,012 | 7 payments
|
| Gilead Sciences | None | $3,040 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $3,000 | 1 payment
|
| Novartis Pharmaceuticals | None | $528 | 1 payment
|
2022: $6,000
| E.R. Squibb & Sons L.L.C. | None | $6,000 | 2 payments
|
2021: $9,500
| Gilead Sciences | None | $9,500 | 1 payment
|
2020: $8,902
| Gilead Sciences | None | $5,902 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $3,000 | 1 payment
|
2019: $14,239
| Gilead Sciences | None | $14,239 | 18 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Gilead Sciences, Inc. · Collaboration Between Stanford University and Gilead Sciences To Evaluate Whether Blocking Mmp-9 Has Tissue-Protective and Anti-Inflammatory Activities in Takayasu Arteritis · 2019 | Their institution | $93,857 |
| Novartis Pharma AG · Rheumatology Ain Pipeline Studies · 2023 | This clinician | $13,171 |
| Eli Lilly and Company · 2019 | This clinician | $700 |
Professional record
- NPI
- 1952310450
- Licence
- CA C54171, MN 34368California C54171: Current · expires 2028-06-30
- Group
- Mayo Clinic
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 200 1st St Sw, Rochester, MN, 55905
- NPI first listed
- 2006-08-05
- NPI last updated
- 2021-04-16
- NPI record certified
- 2021-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305
This office lists an electronic records connection.